Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;146(1):197-203.
doi: 10.1007/s00432-019-03043-6. Epub 2019 Oct 10.

Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment

Yang Ni  1 , Xin Ye  2 , Xia Yang  1 , Guanghui Huang  1 , Wenhong Li  1 , Jiao Wang  1 , Xiaoying Han  1 , Zhigang Wei  1 , Min Meng  1
Affiliations

Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment

Yang Ni et al. J Cancer Res Clin Oncol. 2020 Jan.

Abstract

Objectives: Evidence from multiple clinical trials showed that local consolidative therapy (LCT) improved survival in oligometastatic non-small cell lung cancer (NSCLC) patients. In the present study, we aim to explore the potential role of microwave ablation (MWA) as LCT for epidermal growth factor receptor (EGFR)-mutant advanced NSCLC patients with extracranial oligometastasis.

Materials and methods: From January 2015 to December 2018, a total of 86 EGFR-mutant stage IIIB or IV NSCLC patients with extracranial oligometastasis were enrolled for retrospective analysis. MWA was used as LCT for all oligometastatic lesions and/or primary tumors in 34 patients without progression after first-line EGFR-TKIs therapy (consolidation group), while the other 52 patients received only TKIs until disease progression (monotherapy group). We calculated and compared the progression-free survival (PFS) and overall survival (OS) of the two groups.

Results and conclusion: Patients with MWA consolidation therapy had significantly improved PFS (median 16.7 vs. 12.9 months, HR 0.44, 95% CI 0.22-0.88, P = 0.02) and OS (median: 34.8 vs. 22.7 months, HR 0.45, 95% CI 0.24-0.88, P = 0.04) than monotherapy group. MWA for LCT was identified as the independent predictive factor for better PFS (HR 0.46, 95% CI 0.37-0.82, P < 0.01) and OS (HR 0.57, 95% CI 0.33-0.91, P = 0.02). Most toxicities were mild and well tolerated. No patient had to discontinue EGFR-TKIs because of MWA complications. These findings suggest that MWA as local consolidative therapy after first-line EGFR-TKIs treatment leads to better disease control and survival than TKIs monotherapy in EGFR-mutant advanced NSCLC patients with extracranial oligometastasis. MWA as a novel option of LCT might be considered for clinical management of these patients.

Keywords: EGFR-TKIs; Local consolidative therapy; Microwave ablation; Non-small cell lung cancer; Oligometastasis.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Flow chart of patients’ treatments
Fig. 2
Fig. 2
PFS and OS between MWA consolidation group and TKIs monotherapy group
See this image and copyright information in PMC

References

    1. de Baere T, Tselikas L, Catena V, Buy X, Deschamps F, Palussiere J (2016) Percutaneous thermal ablation of primary lung cancer. Diagn Interv Imaging. 97(10):1019–1024 - PubMed
    1. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 17(12):1672–1682 - PMC - PubMed
    1. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 8:JCO1900201 - PMC - PubMed
    1. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10 - PubMed
    1. Inal A, Kodaz H, Odabas H, Duran AO, Seker MM, Inanc M et al (2018) Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: a retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). J Cancer Res Ther. 14(3):578–582 - PubMed

MeSH terms